The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > Companies Unite to Advance Regulatory Landscape of Abuse Potential Assessment

Companies Unite to Advance Regulatory Landscape of Abuse Potential Assessment

Posted 01 September 2011 | By Beatriz RochaHeddie MartynowiczRolW. UsherAndrew FriedmanJonathon ParkerRichard FanelliSuzanne Thornton-JonesCynthia AronsMark Ammann 

The US Food and Drug Administration (FDA) is collaborating with private and public stakeholders in an effort to address critical public health needs and to bridge scientific gaps.1 One of these collaborations focuses on abuse potential and involves three key groups: the Controlled Substance Staff (CSS) of FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Cross Company Abuse Liability Consortium (CCALC).

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe